Percutaneous penetration enhancement in transdermal drug delivery

Asian Journal of Pharmaceutics

Volumn 4, Issue 2, 2010, Pages 92-101

  Singh, Inderjeet ^a   Sri, Prasanthi ^a  

^a UNIVERSITY OF NOTTINGHAM MALAYSIA CAMPUS   (Malaysia)

Author keywords

Biological enhancement; chemical enhancement; drug formulation; drug modification; percutaneous penetration; physical enhancement; transdermal drug delivery

Indexed keywords

1 METHYL 2 PYRROLIDINONE; 2 PYRROLIDINONE; ALCOHOL; ALPRENOLOL; ATENOLOL; ENZYME; FATTY ACID; HYDROXYPROPYLMETHYLCELLULOSE; IBUPROFEN; LAUROCAPRAM; LIDOCAINE; LIPOSOME; MELOXICAM; MENTHOL; MORPHINE; MORPHINE DERIVATIVE; MORPHINE ENANTHATE; MORPHINE PROPIONATE; NAPROXEN; NIOSOME; OLEIC ACID; PIPERAZINE DERIVATIVE; POVIDONE; PRODRUG; PROPRANOLOL; SULFOXIDE; SURFACTANT; TERPENE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WATER;

BIOACCUMULATION; CONCENTRATION (PARAMETERS); CRYSTALLIZATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG FORMULATION; DRUG PACKAGING; DRUG PENETRATION; DRUG SOLUBILITY; DRUG TRANSPORT; ELECTROPORATION; ENCAPSULATION; FIRST PASS EFFECT; HUMAN; IONIZATION; IONTOPHORESIS; LIPID BILAYER; LIVER METABOLISM; MATHEMATICAL COMPUTING; MELTING POINT; MICROTECHNOLOGY; NEEDLE; PH; PHYSICAL CHEMISTRY; RACEMIC MIXTURE; REVIEW; SKIN; SKIN IRRITATION; SKIN PERMEABILITY; STEADY STATE; THERMODYNAMICS; TRANSDERMAL DRUG ADMINISTRATION; ULTRASOUND; WATER CONTENT;

EID: 77956252301     PISSN: 09738398     EISSN: 1998409X     Source Type: Journal    
DOI: 10.4103/0973-8398.68459     Document Type: Review

References (80)

1. Liu PC, Bergstrom TK. Quantitative evaluation of aqueous isopropyl alcohol enhancement on skin flux of terbuteline (sulfate). 2. Permeability contributions of equilibrated drug species across human skin in vitro. J PharmSci 1996;85:320-325
2. Valenta C, Siman U, Kratzel M, Hadgraft J. The dermal delivery of lignocaine: Influence of ion pairing. Int J Pharm 2000;197:77-85.
3. Boroujerdi M. Kinetics of ion-pair absorption. Drug Dev Ind Pharm 1987;13:181-191
4. Takahashi K, Rytting JH. Novel approach to improve ondansetron across snake skin as model membrane. J Pharm Pharmacol 2001;53:789-794
5. Zhang J Y, Fang L, Tan Z, Wu J, He ZG. Influence of ion-pairing and chemical enhancers on the transdermal delivery of meloxicam. Drug Dev Ind Phar 2009;35:663-670
6. Neubert R. Ion pair transport across membranes. Pharm Res 1989;6: 743-747
7. Higuchi T. Physical chemical analysis of percutaneous absortion from creams and oitments. J Soc Cosmet Chem 1959;11:85-97.
8. Megrab NA, Williams AC, Barry B W. Oestridiol permeation through human skin and silastic membrane: Effect of propylene glycol and supersaturation. J Control Release 1995;36:277-294
9. Davis A F, Barry BW. Effect of supersaturation on membrane transport. 1. Hydrocortisone acetate. Int J Pharm 1991;76:1-8.
10. Monica LR, Stuart AJ, Marc BB. Transient drug supersaturation kinetics of beclomethasone dipropionate in rapidly drying films. International Journal of Pharmaceutics 2009; 371:114-119
11. Leveque N, Raghavan SL, Lane ME, Hadgraf J. Use of a molecular form technique for the penetration of supersaturated solutions of salicylic acid across silicone membranes and human skin in vitro. Int J Pharm 2006;318:49-54.
12. Hadgraft J. Skin deep. Eur J Pharm Biopharm 2004;58:291-299
13. Martin A. Physical Chemical Principles in the Pharmaceutical Sciences. Philadelphia, Lea and Febiger: Lippincott Williams and Wilkins; 1993.
14. Hemstrom CA, Evans RL, Lobeck FG. Haloperidol decanoate: A depot antipsychotic. Drug Intell Clin Pharm 1988;22:290-295
15. Albert A. Chemical aspects of selective toxicity. Nature 1958;182: 421-423
16. Rautio J, Nevalainen T, Taipale H. Piperazinyalkyl prodrug of naproxen improve in vitro skin permeation. Eur J Pharm Sci 2000;11:157-163
17. Wang JJ, Sung KC, Huang J F, Yeh CH, Fang JY. Ester prodrugs of morphine improve transdermal drug delivery: A mechanistic study. J Pharm Pharmacol 2007;59:917-925
18. Morris AP, Brain KR, Heard CM. Skin permeation and ex-vivo skin metabolism of O-acyl haloperidol ester prodrugs. Int J Pharm 2009;367:44-50.
19. Thorsteinsson T, Másson M, Jarvinen T, Nevalainen T, Loftsson T. Cycloserine fatty acid derivatives as prodrugs: synthesis, degradation and in vitro skin permeability. Chem Pharm Bull (Tokyo) 2002;50: 554-557
20. Touitou E, Chow DD, Lawter JR. Chiral beta-blockers for transdermal delivery. Int J Pharm 1994;104:19-28.
21. Stott P W, Williams AC, Barry BW. Transdermal delivery from eutectic systems: Enhanced permeation of a model drug, ibuprofen. J Control Release 1998;50:297-308.
22. Kang LS, Jun HW, McCall JW. Physicochemical studies of lidocaine-menthol binary systems for enhanced membrane transport. Int J Pharm 2000;206:35-42.
23. Magnusson BM, Walters KA, Roberts MS. Veterinary drug delivery: Potential for skin penetration enhancement. Adv Drug Deliv Rev 2001;50:205-227
24. Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev 2004;56:603-618
25. Idson B. Hydration and percutaneous absorption. Curr Probl Dermatol 1978;7:132-141
26. nd ed. New York: Marcel Dekker; 2006.
27. van Hal DA, Jeremiasse E, Junginger HE, Spies F, Bouwstra JA. Structure of fully hydrated human stratum Cornrum: A freeze fracture electron microscopy study. J Invest Dermatol 1996;106:89-95.
28. Kligman AM. Topical pharmacology and toxicology of dimethysulfoxide. JAMA 1965;193:796-804.
29. Southwell D, Barry BW. Penetration enhancers for human skin: Mode of action of 2-pyrrolidone and dimethylformamide on partition and diffusion of model compounds water, n-alcohols and caffeine. J Invest Dermatol 1983;80:507-515
30. Wiechers J W, Drenth B F, Jonkman JH, de Zeeuw RA. Percutaneous absorption and elimination of the penetration enhancer azone in humans. Pharm Res 1987;4:519-523
31. Pilgram GS, van der Meulen J, Gooris GS, Koerten HK, Bouwstra JA. The influence of two azones and sebaceous lipids on the lateral organisation of lipids isolated from human stratum corneum. Biochimica et Biophysica Acta 2001;1511:244-254
32. ® (1-dodecylazacycloheptan-2-one) on herpes simplex viruses. Chemotherapy 1987;33:151-156
33. Aungst BJ, Rogers NJ, Shefter E. Enhancement of naloxone penetration through human skin in vitro using fatty acids, fatty alcohols, surfactants, sulfoxides and amines. Int J Pharm 1986;33:225.
34. Ongpipattanakul B, Burnette RR, Potts RO, Francoeur ML. Evidence that oleic acid exist in a separate phase within stratum corneum lipids. Pharm Res 1991;7:350-354
35. Smith EW, Maibach HI. Percutaneous penetration enhancers. Boca Raton, FL: CRC/Taylor and Francis; 2005.
36. Thong HY, Zhai H, Maibach HI. Percutaneous penetration enhancers: An overview. Skin Pharmacol Physiol 2007;20:272-282
37. Friend DS, Catz P, Heller J, Reid J, Baker R. Simple alkyl esters as skin permeation enhancers. J Control Release 1989; 9:33.
38. Bergstrom TK, Knutson K, De Noble LJ, Goates C Y. Percutaneous absorption enhancement of an ionic molecule by ethanol-water systems in human skin. Pharm Res 1990;7:762-766
39. Megrab NA, Williams AC, Barry BW. Oestradiol permeation across human skin, silastic and snake skin membranes: The effects of ethanol/water co-solvent systems. Int J Pharm 1995;116:101-112
40. Williams AC. Transdermal and topical drug delivery: From theory to clinical practise. London: Pharmaceutical Press; 2003.
41. Tan EL, Liu JC, Chien Y W. Effect of cationic surfactants on the transdermal permeation of ionized indomethacin. Drug Dev Ind Pharm 1993;19:685.
42. Ghosh TK, Habib MJ, Childs K, Alexander M. Transdermal delivery of metoprolol comparison between hairless mouse and human cadaver skin and effect of n-decylmethyl sulfoxide. Int J Pharm 1992;88:391-396
43. Rosten M. The treatment of ichthyosis and hyperkeratotic conditions with urea. Australas J Dermatol 1970;11:142-144
44. Garala K, Faldu N, Basu B, Bhalodia R, Mehta K, Joshi B. Chemical penetration enhancement. J Pharm Res 2009;2:1804-1808
45. Wong O, Tsuzuki N, Nghiem B, Kuehnhoff J, Itoh T, Masaki K, et al. Unsaturated cyclic ureas as new non-toxic biodegradable transdermal penetration enhancers: II. Evaluation study. Int J Pharm 1989;52:191-192
46. Aqil M, Ahad A, Sultan Y, Ali A. Status of terpenes as skin penetration enhancers. Drug Discov Today 2007;12:1061-1067
47. Vaddi HK. Terpenes in propylene glycol as skin-penetration enhancers: Permeation and partition of haloperidol, fourier transform infrared spectroscopy and differential scanning calorimetry. J Pharm Sci 2002;91:1639-1651
48. Weiner N, Williams N, Birch G. Topical delivery of liposomally encapsulated interferon evaluated in cutaneous herpes guinea pig model. Antimicrob Agents Chemother 1989;33:1217-1221
49. Madza F, Ozer AY, Ercan MT, Hincal AA. Preparation and characterisation of urea niosomes: Invitro and in vivo studies. STP Pharm Sci 1997;7: 205-214
50. Cevc G. Transfersomes, liposomes and other lipid uspensions on the skin: Permeation advancement, vesicle penetration and transdermal drug delivery. Crit Rev Ther Drug Carrier Syst 1996;13:257-388.
51. Cevc G, Blume G. Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradient and hydration force. Biochimica et Biophysica Acta 1992;1104:226-232
52. Touitou E, Godin B, Dayan N. Enhanced delivery of drugs into and across the skin by ethosomal carriers. Drug Dev Res 2000;50:406-415
53. Dean HJ, Fuller D, Osorio JE. Powder and particle-mediated approaches for delivery of DNA and protein vaccines into the epidermis. Comp Immunol Microbiol Infect Dis 2003;26:373-388
54. Jacques SL, McAuliffe DJ, Blank IH, Parrish JA. Controlled removal of human stratum corneum by pulsed laser. J Invest Dermatol 1987;88: 88-93.
55. Nelson JS, McCullough JL, Glenn TC. Mid-infrared laser ablation of stratum corneum enhances in vitro percutaneous transport of drugs. J Invest Dermatol 1991;97:874-879
56. Henry S, McAllister D V, Allen MG, Prausnitz MR. Microfabricated microneedles: A novel approach to transdermal drug delivery. J Pharm Sci 1998;87:922-925
57. Prausnitz MR. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev 2004;56:581-587
58. Kaushik S, Hord AH, Denson DD, McAllister D V, Smitra S, Allen MG, et al. Lack of pain associated with microfabricated microneedles. Anesth Analg 2001;92:502-504
59. McAllister D V, Patel PN, Mayberry JL, Allen MG, Prausnitz MR. Solid and hollow microneedles for transdermal drug delivery. Proceding in International Sympossium-Controled Release of Bioactive Materials. Boston: Deerfield, IL; 1999. p. 192-193
60. Tachibana K, Tachibana S. Transdermal delivery of insulin by ultrasonic vibration. J Pharm Pharmacol 1991;43:270-271
61. Mitragotri S, Edwards D, Blankschtein D, Langer R. A mechanistic study of ultrasonically enhanced transdermal drug delivery. J Pharm Sci 1995;184:697-706.
62. Banga AK, Bose S, Ghosh TK. Iontophoresis and electroporation: Comparisons and contrasts. Int J Pharm 1999;179:1-19.
63. Dixit N, Bali V, Baboota S, Ahuja A, Ali J. Iontophoresis: An approach for controlled drug delivery: A review. Curr Drug Deliv 2007;4:1-10.
64. Phipps JB, Padmanabhan RV, Lattin GA. Iontophoresis delivery of model inorganic and drug ion. J Pharm Sci 1989;78:365-369
65. Yoshida NH, Roberts MS. Solute molecular size and transdermal iontoporesis across excised human skin. J Control Release 1993;25: 177-195
66. Lopez R F, Bentley MV, Delgado-Charro MB, Guy RH. Iontophoretic delivery of 5-aminolevulinic acid (ALA): Effect of pH. Pharm Res 2001;18:311-315
67. Pillai O, Nair V, Panchagnula R. Transdermal iontophoresis of insulin: I V. Influence of chemical enhancers. Int J Pharm 2004;269:109-120
68. Cullander C, Guy RH. Sites of iontophoretic current flow into the skin: Identification and characterization with the vibrating probe electrode. J Invest Dermatol 1991;97:55-64.
69. Prausnitz MR, Gimm JA, Guy RH, Langer R, Weaver JC, Cullander C. Imaging regions of transport across human stratum corneum during high-voltage and low-voltage exposures. J Pharm Sci 1996;85:1363-1370
70. Medi BM, Hoselton S, Marepalli RB, Singh J. Skin targeted DNA vaccine delivery using electroporation in rabbits: I: Efficacy. Int J Pharm 2005;294:53-63.
71. Wallace MS, Ridgeway B, Jun E, Schulteis G, Rabussay D, Zhang L. Topical delivery of lidocaine in healthy volunteers by electroporation, electroincorporation, or iontophoresis: an evaluation of skin anesthesia. Reg Anesth Pain Med 2001;26:229-238
72. Wu QH, Liang WQ, Bao JL, Ping QN. Enhanced transdermal delivery of tetracaine by electroporesion. Int J Pharm 2000;202:121-124
73. Conjeevaram R, Banga AK, Zhang L. Electrically modulated transdermal delivery of fentanyl. Pharm Res 2002;19:440-444
74. Meidan VM, Al-Khalili M, Michniak BB. Enhanced iontophoretic delivery of buspirone hydrochloride across human skin using chemical enhancers. Int J Pharm 2003;264:73-83.
75. Prausnitz MR. A practical assessment of transdermal drug delivery by skin electroporation. Adv Drug Deliv Rev 1999;35:61-76.
76. Lampe MA, Burlingame AL, Whitney J, Williams ML, Brown BE, Roitman E, et al. Human stratum corneum lipids: Characterization and regional variations. J Lipid Res 1983;24:120-130
77. Holleran WM, Takagi Y, Feingold KR, Menon GK, Legler G, Elias PM. Processing of epidermal glucosylceremides is required for optimal mammalian permeability barrier function. J Clin Invest 1993;91:1656-1664
78. Zuo Y, Zhuang DZ, Han R, Isaac G, Tobin JJ, McKee M, et al. ABCA12 maintains the epidermal lipid permeability barrier by facilitating formation of ceramide linoleic esters. J Biol Chem 2008;283:36624-36635
79. Bouwstra J, Pilgram G, Gooris G, Koerten H, Ponec M. New aspects of the skin barrier organization. Skin Pharmacol Appl Skin Physiol 2001;14:52-62.
80. Jui CT, Richard HG, Carl RT, Wen-Ni G, Kenneth R F, Peter ME. Metabolic approaches to enhance transdermal drug delivery. 1. Effect of lipid synthesis inhibitors. J Pharm Sci 1996;85:643-648